Benzimidazolone derivatives with central dopaminergic activity

• US 5,883,094 A
• Filed: 03/11/1997
• Issued: 03/16/1999
• Est. Priority Date: 04/24/1995
• Status: Expired due to Fees

• Current Assignee: Pfizer Inc.
• Original Assignee: Pfizer Inc.
• Inventors: O'Neill, Brian T., Faraci, William S., Fliri, Anton F-J., Sanner, Mark A., Zorn, Stevin H.
• Primary Examiner(s): Grumbling, Matthew V.
• Application Number:
  US08/750,479
• Time in Patent Office: 735 Days
• Field of Search: 544/295, 544/182, 544/357, 544/238, 544/360, 546/194, 514/242, 514/253, 514/318
• US Class Current: 514/242
• CPC Class Codes: C07D 235/26 Oxygen atoms
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links

Abstract

This invention relates to novel, pharmaceutically active benzimidazolone derivatives of the formula ##STR1## wherein the dashed line, R⁰ through R⁶ and X¹ through X³ are defined as in the specification. These compounds exhibit central dopaminergic activity and are u in the treatment of CNS disorders.

Claims

1. A compound of the formula ##STR4## wherein X¹, X² and X³ are independently selected from carbon and nitrogen;

R⁰, R¹ and R² are independently selected from hydrogen, halo, (C₁ -C₆)alkyl optionally substituted with from one to three fluorine atoms and (C₁ -C₆)alkoxy optionally substituted with from one to three fluorine atoms;

R³ is hydrogen, (C₁ -C₆)alkyl or benzyl, wherein the phenyl moiety of said benzyl group may optionally be substituted with from one or more substituents, independently selected from halo, cyano, (C₁ -C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁ -C₆)alkoxy optionally substituted with from one to three fluorine atoms, (C₁ -C₆)alkylsulfonyl, (C₁ -C₆)alkylamino, amino, di-(C₁ -C₆)alkylamino and (C₁ -C₆)carboxamido;

R⁴, R⁵ and R⁶ are independently selected from hydrogen, halo, cyano, (C₁ -C₆)alkyl optionally substituted with from one to three fluorine atoms, (C₁ -C₆)alkoxy optionally substituted with from one to three fluorine atoms, (C₁ -C₆)alkylsulfonyl, (C₁ -C₆)acylamino, (phenyl) (C₁ -C₆)acyl!amino, amino, (C₁ -C₆)alkylamino and di-(C₁ -C₆)alkylamino; and

the dashed line represents an optional double bond;

with the proviso that when X³ is nitrogen, R² is absent;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein X² is nitrogen.

3. A compound according to claim 2, wherein R¹ is bromine or chlorine.

4. A compound according to claim 1, wherein said compound is selected from the group consisting of:

1- 3-(4-pyridin-2-yl-piperazin-1-yl)-propyl!-1,3-dihydro-benzoimidazol-2-one;

1-{3- 4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl!-propyl}-1,3-dihydro-benzoimidazol-2-one;

1-{3- 4-(5-chloro-pyridin-2-yl)-piperazin-1-yl!-propyl}-1,3-dihydro-benzoimidazol-2-one;

1-{3- 4(5-bromo-pyridin-2-yl)-piperazin-1-yl!-propyl}-1,3dihydro-benzoimidazol-2-one;

1- 3-(2,3,5,6-tetrahydro- 1,2!bipyrazinyl-4-yl)-propyl!-1,3-dihydro-benzoimidazol-2-one; and

1-{3- 4-(6-chloro-pyridazin-3-yl)-piperazin-1-yl!-propyl}-1,3-dihydro-benzoimidazol-2-one.

5. A pharmaceutical composition for treating a condition selected from sleep disorders, sexual disorders, gastrointestinal disorders, psychosis, affective psychosis, nonorganic psychosis, personality disorders, psychiatric mood disorders, conduct and impulse disorders, schizophrenic and schizoaffective disorders, polydipsia, bipolar disorders, dysphoric mania, anxiety and related disorders, obesity, emesis, bacterial infections of the CNS, learning disorders, memory disorders, Parkinson'"'"'s disease, depression, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, hypothalamic pituitary disorders, congestive heart failure, chemical dependencies, vascular and cardiovascular disorders, ocular disorders, dystonia, tardive dyskinesia, Gilles De LaTourette'"'"'s syndrome and other hyperkinesias, dementia, ischemia, Parkinson'"'"'s disease, akathesia and other movement disorders, hypertension and diseases caused by a hyperactive immune system such as allergies and inflammation in a mammal, comprising an amount of a compound according to claim 1 that is effective in treating such condition, and a pharmaceutical acceptable carrier.

6. A pharmaceutical composition for treating a condition selected from sleep disorders, sexual disorders, gastrointestinal disorders, psychosis, affective psychosis, nonorganic psychosis, personality disorders, psychiatric mood disorders, conduct and impulse disorders, schizophrenic and schizoaffective disorders, polydipsia, bipolar disorders, dysphoric mania, anxiety and related disorders, obesity, emesis, meningitis and other bacterial infections of the CNS, learning disorders, memory disorders, Parkinson'"'"'s disease, depression, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, hypothalamic pituitary disorders, congestive heart failure, chemical dependencies, vascular and cardiovascular disorders, ocular disorders, dystonia, tardive dyskinesia, Gilles De La Tourette'"'"'s syndrome and other hyperkinesias, dementia, ischemia, Parkinson'"'"'s disease, akathesia and other movement disorders, hypertension and diseases caused by a hyperactive immune system such as allergies and inflammation in a mammal, comprising a dopaminergic effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition for treating a disease or condition, the treatment or prevention of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, comprising a dopaminergic effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition for treating a condition selected from sleep disorders, sexual disorders, gastrointestinal disorders, psychosis, affective psychosis, nonorganic psychosis, personality disorders, psychiatric mood disorders, conduct and impulse disorders, schizophrenic and schizoaffective disorders, polydipsia, bipolar disorders, dysphoric mania, anxiety and related disorders, obesity, emesis, meningitis and other bacterial infections of the CNS, learning disorders, memory disorders, Parkinson'"'"'s disease, depression, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, hypothalamic pituitary disorders, congestive heartfailure, chemical dependencies, vascular and cardiovascular disorders, ocular disorders, dystonia, tardive dyskinesia, Gilles De La Tourette'"'"'s syndrome and other hyperkinesias, dementia, ischemia, Parkinson'"'"'s disease, akathesia and other movement disorders, hypertension and diseases caused by a hyperactive immune system such as allergies and inflammation in a mammal, comprising a D4 receptor binding effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition for treating a disease or condition, the treatment or prevention of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, comprising a D4 receptor binding effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

10. A method of treating a condition selected from sleep disorders, sexual disorders, gastrointestinal disorders, psychosis, affective psychosis, nonorganic psychosis, personality disorders, psychiatric mood disorders, conduct and impulse disorders, schizophrenic and schizoaffective disorders, polydipsia, bipolar disorders, dysphoric mania, anxiety and related disorders, obesity, emesis, meningitis and other bacterial infections of the CNS, learning disorders, memory disorders, Parkinson'"'"'s disease, depression, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, hypothalamic pituitary disorders, congestive heart failure, chemical dependencies, vascular and cardiovascular disorders, ocular disorders, dystonia, tardive dyskinesia, Gilles De La Tourefte'"'"'s syndrome and other hyperkinesias, dementia, ischemia, Parkinson'"'"'s disease, akathesia and other movement disorders, hypertension and diseases caused by a hyperactive immune system such as allergies and inflammation in a mammal, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such a condition.

11. A method of treating a condition selected from sleep disorders, sexual disorders, gastrointestinal disorders, psychosis, affective psychosis, nonorganic psychosis, personality disorders, psychiatric mood disorders, conduct and impulse disorders, schizophrenic and schizoaffective disorders, polydipsia, bipolar disorders, dysphoric mania, anxiety and related disorders, obesity, emesis, meningitis and other bacterial infections of the CNS, learning disorders, memory disorders, Parkinson'"'"'s disease, depression, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, hypothalamic pituitary disorders, congestive heart failure, chemical dependencies, vascular and cardiovascular disorders, ocular disorders, dystonia, tardive dyskinesia, Gilles De La Tourette'"'"'s syndrome and other hyperkinesias, dementia, ischemia, Parkinson'"'"'s disease, akathesia and other movement disorders, hypertension and diseases caused by a hyperactive immune system such as allergies and inflammation in a mammal, comprising an administering to said mammal a dopaminergic effective amount of a compound according to claim 1.

12. A method of treating a disease or condition, the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, comprising administering to said mammal a dopaminergic effective amount of a compound according to claim 1.

13. A method of treating a condition selected from sleep disorders, sexual disorders, gastrointestinal disorders, psychosis, affective psychosis, nonorganic psychosis, personality disorders, psychiatric mood disorders, conduct and impulse disorders, schizophrenic and schizoaffective disorders, polydipsia, bipolar disorders, dysphoric mania, anxiety and related disorders, obesity, emesis, meningitis and other bacterial infections of the CNS, learning disorders, memory disorders, Parkinson'"'"'s disease, depression, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, hypothalamic pituitary disorders, congestive heart failure, chemical dependencies, vascular and cardiovascular disorders, ocular disorders, dystonia, tardive dyskinesia, Gilles De La Tourette'"'"'s syndrome and other hyperkinesias, dementia, ischemia, Parkinson'"'"'s disease, akathesia and other movement disorders, hypertension and diseases caused by a hyperactive immune system such as allergies and inflammation in a mammal, comprising an administering to said mammal a D4 receptor binding effective amount of a compound according to claim 1.

14. A method of treating a disease or condition, the treatment or prevention of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, comprising administering to said mammal a D4 receptor binding effective amount of a compound according to claim 1.

15. A compound as claimed in claim 1 wherein the phenyl moiety of benzyl in the definition of R³ may optionally be substituted with from one to three substituents.